Moonlake ImmunotherapeuticsMLTX
13F holders, Q2 2025 (June 30)1holders
0new positions
0sold out
$47.20avg. 13F price*
At the end of Q2 2025, 1 institutions reported holding Moonlake Immunotherapeutics (MLTX) in their 13F filings, unchanged from Q1 2025. 0 opened new positions and 0 sold out. The largest holder was Decheng Capital LLC ($8.6M).
- Company
- Moonlake Immunotherapeutics
- CUSIP
- G4444C102
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 10,000 shares bought, net +10,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Decheng Capital LLC | 2.17% | Add +5.8% | 181,600 | $8.6M |
"% of holder's portfolio" is MLTX's weight in each manager's 13F, not the share of Moonlake Immunotherapeutics the manager owns.